Collectively, our data suggest that the TGF-β1/SMAD3 axis is critical for the regulation of the anti-tumor activities of CD44+CD8+ T cells by CRC cell-expressed ATP6V0A1. The gene discussed is CD8A; the disease is neoplasm.